Literature DB >> 30006871

Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.

Eiichiro Kanda1,2, Naoki Kashihara2, Kunihiro Matsushita3, Tomoko Usui4, Hirokazu Okada5, Kunitoshi Iseki6, Kenichi Mikami7, Tetsuhiro Tanaka8, Takashi Wada9, Hirotaka Watada10, Kohjiro Ueki11, Masaomi Nangaku12.   

Abstract

Entities:  

Keywords:  Chronic kidney disease; Dialysis; End-stage renal disease; Glomerular filtration rate; Guideline; Proteinuria; Surrogate endpoint

Mesh：

Year:  2018        PMID： 30006871     DOI： 10.1007/s10157-018-1615-x

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  53 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.

Authors:  Catherine M Clase; Joshua Barzilay; Peggy Gao; Andrew Smyth; Roland E Schmieder; Sheldon Tobe; Koon K Teo; Salim Yusuf; Johannes F E Mann
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

3.  Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Authors:  H J L Heerspink; T Ninomiya; F Persson; B M Brenner; P Brunel; N Chaturvedi; A S Desai; S M Haffner; J J V Mcmurray; S D Solomon; M A Pfeffer; H-H Parving; D de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2016-01-13       Impact factor: 6.577

4.  Effect of gender on the progression of nondiabetic renal disease: a meta-analysis.

Authors:  Joel Neugarten; Anjali Acharya; Sharon R Silbiger
Journal:  J Am Soc Nephrol       Date:  2000-02       Impact factor: 10.121

5.  GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.

Authors:  Hiddo J Lambers Heerspink; Hocine Tighiouart; Yingying Sang; Shoshana Ballew; Hasi Mondal; Kunihiro Matsushita; Josef Coresh; Andrew S Levey; Lesley A Inker
Journal:  Am J Kidney Dis       Date:  2014-10-16       Impact factor: 8.860

Review 6.  Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View.

Authors:  Linda F Fried; Julia Lewis
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

7.  Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan.

Authors:  Kunitoshi Iseki; Kozen Kinjo; Chiho Iseki; Shuichi Takishita
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

8.  The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.

Authors:  Tazeen H Jafar; Christopher H Schmid; Paul C Stark; Robert Toto; Giuseppe Remuzzi; Piero Ruggenenti; Carmelita Marcantoni; Gavin Becker; Shahnaz Shahinfar; Paul E De Jong; Dick De Zeeuw; Anne-Lise Kamper; Svend Strangaard; Andrew S Levey
Journal:  Nephrol Dial Transplant       Date:  2003-10       Impact factor: 5.992

9.  Proteinuria and the risk of developing end-stage renal disease.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860
View more
  9 in total

1.  Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.

Authors:  Masanori Iwase; Hitoshi Ide; Toshiaki Ohkuma; Hiroki Fujii; Yuji Komorita; Masahito Yoshinari; Yutaro Oku; Taiki Higashi; Udai Nakamura; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2021-09-28       Impact factor: 2.801

2.  Identifying progressive CKD from healthy population using Bayesian network and artificial intelligence: A worksite-based cohort study.

Authors:  Eiichiro Kanda; Yoshihiko Kanno; Fuminori Katsukawa
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

3.  Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.

Authors:  Fang L Zhou; Hirotaka Watada; Yuki Tajima; Mathilde Berthelot; Dian Kang; Cyril Esnault; Yujin Shuto; Hiroshi Maegawa; Daisuke Koya
Journal:  Diabetes Obes Metab       Date:  2019-06-03       Impact factor: 6.577

4.  Frequency of Breakfast, Lunch, and Dinner and Incidence of Proteinuria: A Retrospective Cohort Study.

Authors:  Ryohei Tomi; Ryohei Yamamoto; Maki Shinzawa; Yoshiki Kimura; Yoshiyuki Fujii; Katsunori Aoki; Shingo Ozaki; Ryuichi Yoshimura; Manabu Taneike; Kaori Nakanishi; Makoto Nishida; Keiko Yamauchi-Takihara; Takashi Kudo; Yoshitaka Isaka; Toshiki Moriyama
Journal:  Nutrients       Date:  2020-11-19       Impact factor: 5.717

Review 5.  Bardoxolone methyl: drug development for diabetic kidney disease.

Authors:  Hironori Kanda; Kengo Yamawaki
Journal:  Clin Exp Nephrol       Date:  2020-06-27       Impact factor: 2.801

6.  Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.

Authors:  Nobuya Inagaki; Masaomi Nangaku; Yasushi Sakata; Kazuyo Sasaki; Kazumi Mori-Anai; Tomohisa Iwasaki; Koume Hamada
Journal:  Adv Ther       Date:  2021-12-02       Impact factor: 3.845

7.  Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.

Authors:  Takashi Kadowaki; Nobuya Inagaki; Hirotaka Watada; Kazuyo Sasaki; Kazumi Mori-Anai; Tomohisa Iwasaki; Tatsuki Teranishi
Journal:  Adv Ther       Date:  2022-02-09       Impact factor: 3.845

8.  Time to doubling of serum creatinine in patients with diabetes in Ethiopian University Hospital: Retrospective follow-up study.

Authors:  Adeladlew Kassie Netere; Ashenafi Kibret Sendekie
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

Review 9.  Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis.

Authors:  Lin Zhang; Kang An; Xingyu Mou; Mei Zhang; Qiaoli Su; Shuangqing Li
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.